TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39578039

Group type: EXPERIMENTAL
Intervention: Patient Activated Reliever-Triggered ICS (PARTICS)
Number of subjects: 713

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 713
Study: 39578038

Group type: EXPERIMENTAL
Intervention: DOR/DTG/3TC (co-formulated doravirine, dolutegravir, and lamivudine) once daily
Number of subjects: 210

Group type: COMPARATOR
Intervention: Boosted ART regimen
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: DOR/DTG/3TC
Number of subjects: 210
Study: 39578040

Group type: EXPERIMENTAL
Intervention: Symptomatic patients with active COVID-19
Number of subjects: 311

Group type: COMPARATOR
Intervention: Asymptomatic patients with active COVID-19
Number of subjects: 311

Group type: COMPARATOR
Intervention: Patients who had recovered from COVID-19 prior to surgery
Number of subjects: 311
Study: 39578265

Group type: EXPERIMENTAL
Intervention: High flow nasal cannula (HFNC) at 50 to 60 L.min
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-level continuous positive airway pressure (CPAP) at 4 cmH2O
Number of subjects: 29
Study: 39578309

Group type: EXPERIMENTAL
Intervention: NMES-RT + FES
Number of subjects: 32

Group type: COMPARATOR
Intervention: PMT + FES
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 32
Study: 39578347

Group type: EXPERIMENTAL
Intervention: GN-037 cream
Number of subjects: 190

Group type: COMPARATOR
Intervention: Clobetasol 17-propionate (CP) cream
Number of subjects: 190

Group type: COMPARATOR
Intervention: Vehicle (V) cream
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 190
Study: 39578348

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg every 4 weeks (Q4W)/every 8 weeks (Q8W) initial/maintenance dosing
Number of subjects: 1107
Study: 39578376

Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Tooth brushing more than once a day
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Interdental hygiene
Number of subjects: 1002
Study: 39578602

Group type: EXPERIMENTAL
Intervention: Preoperative vaginal microbiome analysis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vaginal microbiome characterized by low abundance of Lactobacillus and high prevalence of Prevotella and Gardnerella species
Number of subjects: 22
Study: 39578778

Group type: EXPERIMENTAL
Intervention: LDL-cholesterol levels in women
Number of subjects: 231

Group type: COMPARATOR
Intervention: Obesity and serum leptin levels
Number of subjects: 231
Study: 39578819

Group type: EXPERIMENTAL
Intervention: IL-20 levels in patients with MetS and periodontitis
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Correlation of IL-20 with periodontal parameters
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RANKL/OPG levels correlation with IL-20
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxidative stress index (OSI) levels in presence of periodontitis and MetS
Number of subjects: 80
Study: 39578921

Group type: EXPERIMENTAL
Intervention: 1% topical sirolimus applied to the face for 24 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo applied to the face for 24 weeks
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: 1% topical sirolimus
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 39578926

Group type: EXPERIMENTAL
Intervention: Anticholinergic deprescribing intervention
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 344
Study: 39578942

Group type: EXPERIMENTAL
Intervention: CAD-CAM surgical guides
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional surgical guides (control group)
Number of subjects: 27
Study: 39579142

Group type: EXPERIMENTAL
Intervention: Trilaciclib
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study: 39579225

Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation (VF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No ventricular fibrillation (Control)
Number of subjects: 30
Study: 39579274

Group type: EXPERIMENTAL
Intervention: 12-week progressive whole-body resistance exercise training (RET) program
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (postmenopausal breast cancer survivors)
Number of subjects: 13
Study: 39579383

Group type: EXPERIMENTAL
Intervention: KIM technology for real-time image-guided radiotherapy
Number of subjects: 48
Study: 39579408

Group type: COMPARATOR
Intervention: Hyperpronation (HP) maneuver
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Supination/Flexion (SF) maneuver
Number of subjects: 119
Study: 39579605

Group type: EXPERIMENTAL
Intervention: Educational intervention (4 group sessions and 6 telephone calls over 6 months) focusing on physical activity, nutritional habits, cognition, and psychosocial well-being
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual healthcare assistance (Control group)
Number of subjects: 199
Study: 39579782

Group type: EXPERIMENTAL
Intervention: Balloon guide catheter
Number of subjects: 329

Group type: COMPARATOR
Intervention: Conventional guide catheter
Number of subjects: 329

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 329
Study: 39580145

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg every 8 weeks (Q8W)
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg according to a personalized treat-and-extend (T&E)-based regimen
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 1809
Study: 39580357

Group type: EXPERIMENTAL
Intervention: EASE-TR before performance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EASE-TR after performance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EASE-TR
Number of subjects: 100
Study: 39580383

Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet supplemented with soybeans (n=42)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 84
Study: 39580437

Group type: EXPERIMENTAL
Intervention: Empirical antibiotic therapy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Adherence to guidelines for empirical antibiotic therapy
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Adherence to guidelines for therapy duration
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) level exceeding 100 mg/L
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Hospital stay longer than two days
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Planned post-discharge treatment
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Temporal trends in adherence to treatment duration guidelines
Number of subjects: 523
Study: 39580468

Group type: EXPERIMENTAL
Intervention: AADvac1
Number of subjects: 137
Study: 39580601

Group type: EXPERIMENTAL
Intervention: High Synek scale (3 or 4)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: EEG features (discontinuity)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: EEG features (absence of posterior dominant rhythm)
Number of subjects: 125
Study: 39580622

Group type: EXPERIMENTAL
Intervention: Maternal loci associated with HDP (rs114954125 on chromosome 2 near LRP1B)
Number of subjects: 0
Study: 39580793

Group type: EXPERIMENTAL
Intervention: Hydroxyurea and chronic transfusion therapy (HAT)
Number of subjects: 14
Study: 39580964

Group type: EXPERIMENTAL
Intervention: LPG-STJI (single-tract jejunal interposition)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: LPG-DTR (double-tract reconstruction)
Number of subjects: 124

Group type: COMPARATOR
Intervention: LPG-TLR (tube-like stomach reconstruction)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: LPG-STJI
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: LPG-DTR
Number of subjects: 124

Group type: COMPARATOR
Intervention: LPG-TLR
Number of subjects: 124
Study: 39581179

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Conventional fortifier (CF)
Number of subjects: 219
Study: 39581180

Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) lipid emulsion (Lipidem)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard medium/long-chain triglyceride (MCT/LCT) lipid emulsion (reference group)
Number of subjects: 74
Study: 39581197

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg plus platinum-based doublet chemotherapy followed by adjuvant tislelizumab 400 mg every 6 weeks.
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo plus platinum-based doublet chemotherapy followed by placebo every 6 weeks.
Number of subjects: 453
Study: 39581202

Group type: EXPERIMENTAL
Intervention: Mirikizumab 900 mg IV at weeks 0, 4, and 8, then 300 mg SC every 4 weeks from weeks 12 to 52
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Mirikizumab
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1150
Study: 39581330

Group type: EXPERIMENTAL
Intervention: Lampalizumab intervention (exact details not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GA growth rate quartiles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-to-event analysis for BCVA loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cox regression model adjusted for baseline factors
Number of subjects: 0
Study: 39581380

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg orally once daily in continuous 21-day cycles
Number of subjects: 367
Study: 39581426

Group type: EXPERIMENTAL
Intervention: Ventricular leadless pacemaker (VR-LP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Atrial leadless pacemaker (AR-LP)
Number of subjects: 17
Study: 39581486

Group type: EXPERIMENTAL
Intervention: Cu 175 mm intrauterine device
Number of subjects: 1620
Study: 39581541

Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 294

Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 294
Study: 39581631

Group type: EXPERIMENTAL
Intervention: Cenerimod 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cenerimod 2 mg
Number of subjects: 0
Study: 39581701

Group type: COMPARATOR
Intervention: Increased VMHC values in the insula and parahippocampal gyrus in patients with SLE compared to HCs
Number of subjects: 54

Group type: COMPARATOR
Intervention: Reduced grey matter volume in insula and parahippocampal gyrus in patients with SLE compared to HCs
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlation analysis of VMHC values and grey matter volume with cognitive scores and blood biochemical markers in patients with SLE
Number of subjects: 54
Study: 39581714

Group type: EXPERIMENTAL
Intervention: Low-value practices (LVPs) prescribed to female patients
Number of subjects: 978936

Group type: COMPARATOR
Intervention: Low-value practices (LVPs) prescribed to male patients
Number of subjects: 978936

Group type: EXPERIMENTAL
Intervention: Common low-value practices identified
Number of subjects: 978936
Study: 39581719

Group type: EXPERIMENTAL
Intervention: Standardised GP-initiated phone call to evaluate patient's need for urgent care (intervention)
Number of subjects: 4640

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 4640
Study: 39581721

Group type: EXPERIMENTAL
Intervention: Diurnal intermittent enteral nutrition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous enteral feeding
Number of subjects: 30
Study: 39581722

Group type: EXPERIMENTAL
Intervention: Malaria molecular surveillance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategic plan of the Mozambican National Malaria Control Programme (2023-2030)
Number of subjects: 0
Study: 39581724

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG) with oil-based contrast medium
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Hysterosalpingo-foam sonography (HyFoSy)
Number of subjects: 1102
Study: 39581725

Group type: EXPERIMENTAL
Intervention: Suspected preterm labour (SPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls (not exposed to SPL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPL group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children from SPL group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Children from matched controls
Number of subjects: 0
Study: 39581729

Group type: EXPERIMENTAL
Intervention: 1L therapy (first systemic treatment for A/R EC with or without radiotherapy)
Number of subjects: 2376

Group type: COMPARATOR
Intervention: Carboplatin-paclitaxel at 1L
Number of subjects: 2376
Study: 39581737

Group type: EXPERIMENTAL
Intervention: Smart About Meds (SAM) mobile application
Number of subjects: 3250

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3250
Study: 39581739

Group type: COMPARATOR
Intervention: HIV self-testing (HIVST) alone (standard of care)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) and graphic medicine (comic) programme for mental health alongside HIVST
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Combination of HIVST, a livelihoods programme, and mHealth mental health programme
Number of subjects: 330
Study: 39581887

Group type: EXPERIMENTAL
Intervention: 4 implants (4-I)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 6 implants (6-I)
Number of subjects: 47
Study: 39581892

Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET)
Number of subjects: 1250
Study: 39581908

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 85259
Study: 39581957

Group type: EXPERIMENTAL
Intervention: Intravenous omadacycline 100 mg over 0.5 h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oral omadacycline 300 mg
Number of subjects: 9
Study: 39582029

Group type: EXPERIMENTAL
Intervention: 750,000 IU of vitamin D3 via enteral or oral route
Number of subjects: 138

Group type: COMPARATOR
Intervention: 500,000 IU of vitamin D3
Number of subjects: 138
Study: 39582048

Group type: EXPERIMENTAL
Intervention: Curability belief
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Depression (PHQ-9 score ≥ 10)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Interaction of curability belief and depression
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Suspended/stopped anti-cancer treatment
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: End-of-life care settings
Number of subjects: 382
Study: 39582128

Group type: EXPERIMENTAL
Intervention: LY06006
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: EU-DEN
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: US-DEN
Number of subjects: 300
Study: 39582355

Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) intervention
Number of subjects: 78
Study: 39582503

Group type: EXPERIMENTAL
Intervention: 3HP (isoniazid and rifapentine)
Number of subjects: 1655
Study: 39582544

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 611

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 611
Study: 39582551

Group type: EXPERIMENTAL
Intervention: Active Auricular Acupressure Group (AAG)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham Auricular Acupressure Group (SAG)
Number of subjects: 35
Study: 39582666

Group type: EXPERIMENTAL
Intervention: Sucrosomial Vitamin B12 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39582705

Group type: EXPERIMENTAL
Intervention: Enhanced 6-month cardiac rehabilitation program combining exercise training with nutritional intervention (reduction of ultraprocessed food intake, Mediterranean diet, time-restricted eating)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enhanced 6-month cardiac rehabilitation program
Number of subjects: 36
Study: 39582898

Group type: EXPERIMENTAL
Intervention: Zolbetuximab plus CAPOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus CAPOX
Number of subjects: 0
Study: 39582975

Group type: EXPERIMENTAL
Intervention: PMI-targeted pressure support setting strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tidal volume/respiratory rate-targeted group
Number of subjects: 0
Study: 39583146

Group type: EXPERIMENTAL
Intervention: CareSTEPS intervention (n=87)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Usual care (n=87)
Number of subjects: 174
Study: 39583219

Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates identified based on IPC criteria
Number of subjects: 2739

Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with BSA >10%
Number of subjects: 2739

Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with history of psoriasis affecting special areas
Number of subjects: 2739

Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with prior use of topical therapy
Number of subjects: 2739

Group type: EXPERIMENTAL
Intervention: Systemic therapy candidates with PASI scores ≤12
Number of subjects: 2739
Study: 39583653

Group type: EXPERIMENTAL
Intervention: Rescue ITI with efmoroctocog alfa (rFVIIIFc) within 60 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rescue ITI with efmoroctocog alfa (rFVIIIFc)
Number of subjects: 16
Study: 39583881

Group type: EXPERIMENTAL
Intervention: History of catheterization (IUC)
Number of subjects: 196

Group type: COMPARATOR
Intervention: No history of catheterization (Control)
Number of subjects: 196
Study: 39583902

Group type: EXPERIMENTAL
Intervention: Hot-dry (HD) conditions (40°C, 19% relative humidity)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warm-wet (WW) conditions (30°C, 77% relative humidity)
Number of subjects: 12
Study: 39583952

Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg IV every 6 weeks) plus Nivolumab (240 mg IV every 2 weeks)
Number of subjects: 8
Study: 39583953

Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: Quality-of-life scores
Number of subjects: 3635

Group type: EXPERIMENTAL
Intervention: Novel hormonal therapies
Number of subjects: 3635
Study: 39584139

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg enterally once daily for 7 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Metoclopramide 10 mg intravenously every 6-8 hours for 7 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 70

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 70
Study: 39584183

Group type: EXPERIMENTAL
Intervention: Repetitive transorbital alternating current stimulation (rtACS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 16
Study: 39584210

Group type: EXPERIMENTAL
Intervention: Enhanced patient-clinician relationship
Number of subjects: 52

Group type: COMPARATOR
Intervention: Limited patient-clinician relationship
Number of subjects: 52
Study: 39584261

Group type: EXPERIMENTAL
Intervention: CTCA+ICA
Number of subjects: 688

Group type: COMPARATOR
Intervention: ICA only
Number of subjects: 688
Study: 39584292

Group type: EXPERIMENTAL
Intervention: Partnered AdapTango dance (20 min, biweekly for 8 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Home exercise (45 min, biweekly for 8 weeks)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Partnered AdapTango dance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 52
Study: 39584361

Group type: EXPERIMENTAL
Intervention: Management for OL including surveillance, excision, and laser surgery, as well as local and systemic approaches to chemoprevention.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candidate biomarkers and chemoprevention agents.
Number of subjects: 0
Study: 39584380

Group type: EXPERIMENTAL
Intervention: C10 monoclonal antibody (mAb) targeting SARS-CoV-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C10-based Chimeric Antigen Receptor (CAR)-T cells
Number of subjects: 0
Study: 39584464

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) approach with regular text messages for 3 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group with interdental brushing instructions only at baseline and follow-up
Number of subjects: 76
Study: 39584557

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) alone
Number of subjects: 110
Study: 39584789

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) 45 mg/m2, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO)
Number of subjects: 146
Study: 39584867

Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation intensity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39584920

Group type: EXPERIMENTAL
Intervention: Human milk metals and metalloids
Number of subjects: 0
Study: 39585012

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine digluconate (CHX)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 8.7% choline salicylate (CHS)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CON) with no intervention
Number of subjects: 27
Study: 39585174

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study: 39585339

Group type: EXPERIMENTAL
Intervention: Nivolumab + BMS986205 (IDO-inhibitor)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Response-adaptive surgical timing
Number of subjects: 42
Study: 39585451

Group type: EXPERIMENTAL
Intervention: Sleep Low-No Carbohydrates (SL-NCHO)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sleep High-Low Glycemic Index (SH-LGI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sleep High-High Glycemic Index (SH-HGI)
Number of subjects: 42
Study: 39585521

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 272
Study: 39585605

Group type: EXPERIMENTAL
Intervention: High-realistic clinical simulation during baseline visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-realistic clinical simulation during drug administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-realistic clinical simulation during home nursing scenario
Number of subjects: 0
Study: 39585668

Group type: EXPERIMENTAL
Intervention: Children of women with epilepsy (WWE)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Children of healthy women (HW)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Folate supplementation during the first 12 weeks of pregnancy
Number of subjects: 298